AstraZeneca Opens Boston R&D Center | GenomeWeb

Britain’s AstraZeneca has announced the opening of AstraZeneca R&D Boston, the company’s third research facility in North America.


The $100 million research center will employ 130 scientists specializing in infectious diseases and cancer. Additional research will focus on high-throughput screening technologies that enable novel, scientific approaches to pharmaceutical research.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.